News for Oncolys BioPharma Inc. (4588.T)

Published at

Feb 21, 2024 12:07 PM

by globenewswire.com

mixed

mixed

Oncolytic Virus Immunotherapy Market Expected to Reach USD 572.2 million by 2031, Expanding at a 21.1% CAGR | Transparency Market Research, Inc.

The two main drivers driving up the value of the oncolytic virus immunotherapy market are the rising incidence of cancer and the increase in healthcare...

MBIO CADL ONCR MRKD.BA MRK.SN MRK.PA MRK.MX MRK AMGN.MX AMGN.BA AMGN AMG.DE 6MK.DE SRNE REPL ONCY ONC.TO 4588.T 0L85.L

Read more →
Published at

Oct 16, 2023 7:00 PM

by globenewswire.com

mixed

mixed

Frontotemporal Dementia Treatment Drug Market to Showcase Immense Growth During the Study Period (2019–2032) | DelveInsight

The overall frontotemporal dementia market is expected to rise due to increasing prevalence cases over the globe and thus the surge in treatment options....

VCNX SEEL PASG ORYZF ORYN.MX ORY.MC LLY.MX LLY.DE LLY.BA LLY LILY34.SA IONS.MX IONS DNLI ALEC 4588.T 0RDB.L 0Q1G.L 0JDI.L PRTA BIVI APTX ANVS 0Y3M.L

Read more →
Published at

Jun 6, 2023 8:40 AM

by marketscreener.com

negative

negative

ASCO 2023 ANNOUNCEMENT: Encouraging Preliminary Data of OBP-301 with Pembrolizumab in refractory gastroesophageal adenocarcinoma

June 6, 2023 Oncolys BioPharma Inc. ASCO 2023 ANNOUNCEMENT: Encouraging Preliminary Data of OBP-301 with Pembrolizumab... | June 6, 2023

4588.T

Read more →
Published at

Dec 7, 2021 1:17 PM

by globenewswire.com

neutral

neutral

Global Oncolytic Virus Therapy Market to Touch a Revenue of USD 1062.7 Million by 2028; Increasing Investments for Cancer Research and Rising Incidences of Cancer to Accelerate Market Growth

Key Companies Covered in the Oncolytic Virus Therapy Market Research Report Are Amgen Inc., Shanghai Sunway Biotech Co., Ltd., Oncolys BioPharma Inc., TILT...

TRGNF TNG.PA TKBIF PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE ONCR AMGN.MX AMGN.BA AMGN AMG.DE 4974.T 4588.T 0OCQ.L

Read more →
Published at

Dec 7, 2021 7:12 AM

by marketscreener.com

negative

negative

Oncolys BioPharma : First Patient Dosed in NRG Oncology Phase I Clinical Trial for Telomelysin(OBP-301)-Chemoradiation Combination Therapy for Esophageal Cancer Patients

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese... | December 7, 2021

4588.T

Read more →
Published at

Aug 4, 2021 8:06 AM

by marketscreener.com

positive

positive

Oncolys BioPharma : to partner with Thermo Fisher Scientific for viral vector development and GMP manufacturing of their proprietary oncolytic virus, OBP-301

NB: this is a summary translation of the press release August 4, 2021 ... | August 4, 2021

4588.T

Read more →
Published at

Aug 3, 2021 3:30 PM

by prnewswire.com

neutral

neutral

Increasing Adoption of Targeted Cancer Therapies to Propel Oncolytic Virus Immunotherapy Market, Says TMR

/PRNewswire/ -- Oncolytic viruses are being increasingly used in cancer immunotherapy. A number of oncolytic viruses have been extensively studied in clinical...

SRNE REPL ONCY ONCR ONC.TO MRKD.BA MRK.SN MRK.PA MRK.MX MRK AMGN.MX AMGN.BA AMGN AMG.DE 6MK.DE 4588.T 0L85.L

Read more →
Published at

Jul 26, 2021 8:08 AM

by marketscreener.com

positive

positive

Oncolys BioPharma : Announcement of the effect of OBP-2011 against Indian and South African variants of SARS-CoV-2 virus

NB: this is a summary translation of the press release July 26, 2021 ... | July 26, 2021

4588.T

Read more →
Published at

Jul 19, 2021 8:03 AM

by marketscreener.com

neutral

neutral

Oncolys BioPharma : Announcement of manufacturing partnership on OBP-2011, an investigational product for COVID-19

NB: this is a summary translation of the press release Jul 19, 2021 ... | July 19, 2021

4588.T

Read more →